Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $6.87.
The announcement from United Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Overview of Past Earnings
In the previous earnings release, the company beat EPS by $0.10, leading to a 3.05% drop in the share price the following trading session.
Here's a look at United Therapeutics's past performance and the resulting price change:
Quarter
Q1 2025
Q4 2024
Q3 2024
Q2 2024
EPS Estimate
6.53
6.31
6.42
6.40
EPS Actual
6.63
6.19
6.39
5.85
Price Change %
-3.0%
1.0%
3.0%
5.0%
United Therapeutics Share Price Analysis
Shares of United Therapeutics were trading at $298.14 as of July 28. Over the last 52-week period, shares are down 4.04%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analyst Opinions on United Therapeutics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on United Therapeutics.
The consensus rating for United Therapeutics is Neutral, based on 9 analyst ratings. With an average one-year price target of $356.33, there's a potential 19.52% upside.
Comparing Ratings with Competitors
In ...